Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982183 | 0.92 | ADAM17 (0.41) | ADAM17MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4939912 | 0.85 | PTGER4 (0.45) | MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL13992409 | 0.82 | ADRB1 (0.44) | MEN1KMT2A | |
| SCHEMBL4943317 | 0.81 | ALDH1A1 (0.41) | MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL4943283 | 0.81 | PTGER4 (0.40) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4942011 | 0.80 | ACACB (0.47) | — | |
| SCHEMBL4945967 | 0.79 | KMT2A (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4942974 | 0.79 | BCL2 (0.43) | — | |
| SCHEMBL4941608 | 0.79 | PTGER4 (0.51) | — | |
| SCHEMBL4943525 | 0.79 | PTGER4 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | claimed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | claimed |
| EP-1654219-A2 | HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-10 | — | — | EP | claimed |
| WO-2005012232-A2 | HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | claimed |
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | disclosed |
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | disclosed |
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | disclosed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| EP-1654219-A2 | HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012232-A2 | HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | PTGIR, HPGDS, PGF | ADAM17 2192/4885MEN1 4652/4885KMT2A 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.